Robert S. Benjamin, M.D.; Peter H. Wiernik, M.D.; Nicholas R. Bachur, M.D.
This content is PDF only. Please click on the PDF icon to access.
This study was designed to evaluate the efficacy and toxicity of adriamycin in patients with metastatic sarcomas. Thus far 27 patients have been treated; 21 are presently evaluable. The dosage schedule was based on our pharmacologic observations of a long plasma half-life in patients with normal liver function and markedly elevated plasma levels, delayed drug elimination, and severe toxicity in patients with liver disease. One dose, 60 mg/m2 body surface area, was administered intravenously to patients with normal liver function. The dose was reduced by 50% to 75% for patients with liver disease, to achieve plasma levels comparable to those
Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: A New Effective Therapy for Metastatic Sarcoma.. Ann Intern Med. ;78:831. doi: 10.7326/0003-4819-78-5-831_1
Download citation file:
Published: Ann Intern Med. 1973;78(5):831.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use